For the design of next-generation tuberculosis chemotherapy, insight into bacterial defence against drugs is required. Currently, targeting respiration has attracted strong attention for combatting drug-resistant mycobacteria. Q203 (telacebec), an inhibitor of the cytochrome complex in the mycobacterial respiratory chain, is currently evaluated in phase-2 clinical trials.
View Article and Find Full Text PDF